Interferon‑induced transmembrane proteins (IFITMs) are frequently overexpressed in cancer cells, including cervical carcinoma cells, and play a role in the progression of various cancer types. However, their mechanisms of action remain incompletely understood. In the present study, by employing a combination of surface membrane protein isolation and quantitative mass spectrometry, it was comprehensively described how the IFITM1 protein influences the composition of the cervical cancer cell surfaceome. Additionally, the effects of interferon‑γ on protein expression and cell surface exposure were evaluated in the presence and absence of IFITM1. The IFITM1‑regulated membrane and membrane‑associated proteins identified are involved mainly in processes such as endocytosis and lysosomal transport, cell‑cell and cell‑extracellular matrix adhesion, antigen presentation and the immune response. To complement the proteomic data, gene expression was analyzed using reverse transcription‑quantitative PCR to distinguish whether the observed changes in protein levels were attributable to transcriptional regulation or differential protein dynamics. Furthermore, the proteomic and gene expression data are supported by functional studies demonstrating the impact of the IFITM1 and IFITM3 proteins on the adhesive, migratory and invasive capabilities of cervical cancer cells, as well as their interactions with immune cells.

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Zobrazit více v PubMed

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–263. doi: 10.3322/caac.21834. PubMed DOI

D'Augè TG, Donato VD, Giannini A. Strategic approaches in management of early-stage cervical cancer: A comprehensive editorial. Clin Exp Obstet Gynecol. 2024;51:235. doi: 10.31083/j.ceog5110235. DOI

Garg P, Krishna M, Subbalakshmi AR, Ramisetty S, Mohanty A, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochim Biophys Acta Rev Cancer. 2024;1879:189106. doi: 10.1016/j.bbcan.2024.189106. PubMed DOI

D'Oria O, Bogani G, Cuccu I, D'Auge TG, Di Donato V, Caserta D, Giannini A. Pharmacotherapy for the treatment of recurrent cervical cancer: An update of the literature. Expert Opin Pharmacother. 2024;25:55–65. doi: 10.1080/14656566.2023.2298329. PubMed DOI

Bausch-Fluck D, Goldmann U, Müller S, van Oostrum M, Müller M, Schubert OT, Wollscheid B. The in silico human surfaceome. Proc Natl Acad Sci USA. 2018;115:E10988–E10997. doi: 10.1073/pnas.1808790115. PubMed DOI PMC

Friedlová N, Zavadil Kokáš F, Hupp TR, Vojtěšek B, Nekulová M. IFITM protein regulation and functions: Far beyond the fight against viruses. Front Immunol. 2022;13:1042368. doi: 10.3389/fimmu.2022.1042368. PubMed DOI PMC

Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J Biol Chem. 2015;290:25946–25959. doi: 10.1074/jbc.M115.657346. PubMed DOI PMC

Prelli Bozzo C, Nchioua R, Volcic M, Koepke L, Krüger J, Schütz D, Heller S, Stürzel CM, Kmiec D, Conzelmann C, et al. IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat Commun. 2021;12:4584. doi: 10.1038/s41467-021-24817-y. PubMed DOI PMC

Ren L, Du S, Xu W, Li T, Wu S, Jin N, Li C. Current progress on host antiviral factor IFITMs. Front Immunol. 2020;11:543444. doi: 10.3389/fimmu.2020.543444. PubMed DOI PMC

Liao Y, Goraya MU, Yuan X, Zhang B, Chiu SH, Chen JL. Functional involvement of interferon-inducible trans-membrane proteins in antiviral immunity. Front Microbiol. 2019;10:1097. doi: 10.3389/fmicb.2019.01097. PubMed DOI PMC

Gómez-Herranz M, Taylor J, Sloan RD. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. J Biol Chem. 2023;299:102741. doi: 10.1016/j.jbc.2022.102741. PubMed DOI PMC

Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013;9:e1003124. doi: 10.1371/journal.ppat.1003124. PubMed DOI PMC

Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, Jung JU. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe. 2013;13:452–464. doi: 10.1016/j.chom.2013.03.006. PubMed DOI PMC

Rahman K, Datta SAK, Beaven AH, Jolley AA, Sodt AJ, Compton AA. Cholesterol binds the amphipathic helix of IFITM3 and regulates antiviral activity. J Mol Biol. 2022;434:167759. doi: 10.1016/j.jmb.2022.167759. PubMed DOI PMC

Spence JS, He R, Hoffmann HH, Das T, Thinon E, Rice CM, Peng T, Chandran K, Hang HC. IFITM3 directly engages and shuttles incoming virus particles to lysosomes. Nat Chem Biol. 2019;15:259–268. doi: 10.1038/s41589-018-0213-2. PubMed DOI PMC

Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, Klenk HD, Weber F, Herold S, Pöhlmann S, Matrosovich M. pH optimum of hemagglutinin-mediated membrane fusion determines sensitivity of influenza A viruses to the interferon-induced antiviral state and IFITMs. J Virol. 2017;91:e00246–17. doi: 10.1128/JVI.00246-17. PubMed DOI PMC

Wee YS, Roundy KM, Weis JJ, Weis JH. Interferon-inducible transmembrane proteins of the innate immune response act as membrane organizers by influencing clathrin and v-ATPase localization and function. Innate Immun. 2012;18:834–845. doi: 10.1177/1753425912443392. PubMed DOI

Gómez-Herranz M, Nekulova M, Faktor J, Hernychova L, Kote S, Sinclair EH, Nenutil R, Vojtesek B, Ball KL, Hupp TR. The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis. Cell Signal. 2019;60:39–56. doi: 10.1016/j.cellsig.2019.03.024. PubMed DOI PMC

Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–362. doi: 10.1038/nmeth.1322. PubMed DOI

Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: A web server for functional enrichment analysis and functional annotation of gene lists (2021 update) Nucleic Acids Res. 2022;50:W216–W221. doi: 10.1093/nar/gkac194. PubMed DOI PMC

Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, et al. The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2020;49:D605–D612. doi: 10.1093/nar/gkaa1074. PubMed DOI PMC

Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J, Mayer G, Eisenacher M, et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019;47:D442–D450. doi: 10.1093/nar/gky1106. PubMed DOI PMC

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. PubMed DOI PMC

Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: Analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137:e11–e16. doi: 10.1016/j.jid.2016.11.020. PubMed DOI

Suarez-Arnedo A, Figueroa FT, Clavijo C, Arbeláez P, Cruz JC, Muñoz-Camargo C. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS One. 2020;15:e0232565. doi: 10.1371/journal.pone.0232565. PubMed DOI PMC

Aslan M, Hsu EC, Liu S, Stoyanova T. Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay. Biol Methods Protoc. 2021;6:bpab014. doi: 10.1093/biomethods/bpab014. PubMed DOI PMC

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Nekulová M, Wyszkowska M, Friedlová N, Uhrík L, Zavadil Kokáš F, Hrabal V, Hernychová L, Vojtěšek B, Hupp TR, Szymański MR. Biochemical evidence for conformational variants in the anti-viral and pro-metastatic protein IFITM1. Biol Chem. 2024;405:311–324. doi: 10.1515/hsz-2023-0327. PubMed DOI

Gómez-Herranz M, Faktor J, Yébenes Mayordomo M, Pilch M, Nekulova M, Hernychova L, Ball KL, Vojtesek B, Hupp TR, Kote S. Emergent role of IFITM1/3 towards splicing factor (SRSF1) and antigen-presenting molecule (HLA-B) in cervical cancer. Biomolecules. 2022;12:1090. doi: 10.3390/biom12081090. PubMed DOI PMC

Suh HS, Cosenza-Nashat M, Choi N, Zhao ML, Li JF, Pollard JW, Jirtle RL, Goldstein H, Lee SC. Insulin-like growth factor 2 receptor is an IFNgamma-inducible microglial protein that facilitates intracellular HIV replication: Implications for HIV-induced neurocognitive disorders. Am J Pathol. 2010;177:2446–2458. doi: 10.2353/ajpath.2010.100399. PubMed DOI PMC

Pirault J, Polyzos KA, Petri MH, Ketelhuth DFJ, Bäck M, Hansson GK. The inflammatory cytokine interferon-gamma inhibits sortilin-1 expression in hepatocytes via the JAK/STAT pathway. Eur J Immunol. 2017;47:1918–1924. doi: 10.1002/eji.201646768. PubMed DOI

Ferragut F, Vachetta VS, Troncoso MF, Rabinovich GA, Elola MT. ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression. Cytokine Growth Factor Rev. 2021;61:27–37. doi: 10.1016/j.cytogfr.2021.07.001. PubMed DOI

Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, Ye J, Xu C, Qin W, Zhang Z. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol. 2012;33:1619–1628. doi: 10.1007/s13277-012-0417-0. PubMed DOI PMC

Kawada M, Inoue H, Kajikawa M, Sugiura M, Sakamoto S, Urano S, Karasawa C, Usami I, Futakuchi M, Masuda T. A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo. Sci Rep. 2017;7:40400. doi: 10.1038/srep40400. PubMed DOI PMC

Li J, Li Y, Wang H, Shen L, Wang Q, Shao S, Shen Y, Xu H, Liu H, Cai R, Feng W. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer. BMC Cancer. 2023;23:51. doi: 10.1186/s12885-023-10517-x. PubMed DOI PMC

Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses from the KEYNOTE-826 randomized clinical trial. JAMA Oncol. 2024;10:185. doi: 10.1001/jamaoncol.2023.5410. PubMed DOI PMC

Monk BJ, Enomoto T, Kast WM, McCormack M, Tan DSP, Wu X, González-Martín A. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials. Cancer Treat Rev. 2022;106:102385. doi: 10.1016/j.ctrv.2022.102385. PubMed DOI PMC

Kumar Kore R, Shirbhate E, Singh V, Mishra A, Veerasamy R, Rajak H. New investigational drug's targeting various molecular pathways for treatment of cervical cancer: Current status and future prospects. Cancer Invest. 2024;42:627–642. doi: 10.1080/07357907.2024.2373841. PubMed DOI

Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-family proteins: The cell's first line of antiviral defense. Annu Rev Virol. 2014;1:261–283. doi: 10.1146/annurev-virology-031413-085537. PubMed DOI PMC

Liang R, Li X, Zhu X. Deciphering the roles of IFITM1 in tumors. Mol Diagn Ther. 2020;24:433–441. doi: 10.1007/s40291-020-00469-4. PubMed DOI

Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. 2008;105:18490–18495. doi: 10.1073/pnas.0809242105. PubMed DOI PMC

Popson SA, Ziegler ME, Chen X, Holderfield MT, Shaaban CI, Fong AH, Welch-Reardon KM, Papkoff J, Hughes CC. Interferon-induced transmembrane protein 1 regulates endothelial lumen formation during angiogenesis. Arterioscler Thromb Vasc Biol. 2014;34:1011–1019. doi: 10.1161/ATVBAHA.114.303352. PubMed DOI PMC

Wilkins C, Woodward J, Lau DTY, Barnes A, Joyce M, McFarlane N, McKeating JA, Tyrrell DL, Gale M., Jr IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013;57:461–469. doi: 10.1002/hep.26066. PubMed DOI PMC

Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, Planchais C, Porrot F, Guivel-Benhassine F, Van der Werf S, et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 2020;39:e106267. doi: 10.15252/embj.2020106267. PubMed DOI PMC

Chmielewska AM, Gómez-Herranz M, Gach P, Nekulova M, Bagnucka MA, Lipińska AD, Rychłowski M, Hoffmann W, Król E, Vojtesek B, et al. The role of IFITM proteins in tick-borne encephalitis virus infection. J Virol. 2022;96:e0113021. doi: 10.1128/JVI.01130-21. PubMed DOI PMC

Basile A, Zannella C, De Marco M, Sanna G, Franci G, Galdiero M, Manzin A, De Laurenzi V, Chetta M, Rosati A, et al. Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody. Antiviral Res. 2023;211:105546. doi: 10.1016/j.antiviral.2023.105546. PubMed DOI

Meischel T, Fritzlar S, Villalon-Letelier F, Tessema MB, Brooks AG, Reading PC, Londrigan SL. IFITM proteins that restrict the early stages of respiratory virus infection do not influence late-stage replication. J Virol. 2021;95:e0083721. doi: 10.1128/JVI.00837-21. PubMed DOI PMC

Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, Liu SL, Guo F, Geng Y, Qiao W, Liang C. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol. 2014;16:1080–1093. doi: 10.1111/cmi.12262. PubMed DOI PMC

Ishikawa-Sasaki K, Murata T, Sasaki J. IFITM1 enhances nonenveloped viral RNA replication by facilitating cholesterol transport to the Golgi. PLoS Pathog. 2023;19:e1011383. doi: 10.1371/journal.ppat.1011383. PubMed DOI PMC

von Lersner A, Droesen L, Zijlstra A. Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM/CD166. Clin Exp Metastasis. 2019;36:87–95. doi: 10.1007/s10585-019-09957-2. PubMed DOI PMC

Shen X, Li M, Lei Y, Lu S, Wang S, Liu Z, Wang C, Zhao Y, Wang A, Bi C, Zhu G. An integrated analysis of single-cell and bulk transcriptomics reveals EFNA1 as a novel prognostic biomarker for cervical cancer. Hum Cell. 2022;35:705–720. doi: 10.1007/s13577-022-00679-4. PubMed DOI

Owczarek C, Elmasry Y, Parsons M. Contributions of coxsackievirus adenovirus receptor to tumorigenesis. Biochem Soc Trans. 2023;51:1143–1155. doi: 10.1042/BST20221203. PubMed DOI PMC

Liu F, Wu Q, Dong Z, Liu K. Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacol Ther. 2023;247:108458. doi: 10.1016/j.pharmthera.2023.108458. PubMed DOI

Diao B, Sun C, Yu P, Zhao Z, Yang P. LAMA5 promotes cell proliferation and migration in ovarian cancer by activating Notch signaling pathway. FASEB J. 2023;37:e23109. doi: 10.1096/fj.202300306R. PubMed DOI

Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2008;134:365–372. doi: 10.1007/s00432-007-0292-z. PubMed DOI

Yang Y, Koh YW, Sari IN, Jun N, Lee S, Phi LTH, Kim KS, Wijaya YT, Lee SH, Baek MJ, et al. Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer. Int J Cancer. 2019;144:2020–2032. doi: 10.1002/ijc.31926. PubMed DOI PMC

Hatano H, Kudo Y, Ogawa I, Tsunematsu T, Kikuchi A, Abiko Y, Takata T. IFN-induced transmembrane protein 1 promotes invasion at early stage of head and neck cancer progression. Clin Cancer Res. 2008;14:6097–6105. doi: 10.1158/1078-0432.CCR-07-4761. PubMed DOI

Liang Y, Li E, Min J, Gong C, Gao J, Ai J, Liao W, Wu L. MiR-29a suppresses the growth and metastasis of hepatocellular carcinoma through IFITM3. Oncol Rep. 2018;40:3261–3272. PubMed PMC

Zheng W, Zhao Z, Yi X, Zuo Q, Li H, Guo X, Li D, He H, Pan Z, Fan P, et al. Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma. Cancer Cell Int. 2017;17:88. doi: 10.1186/s12935-017-0456-0. PubMed DOI PMC

Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866. doi: 10.3389/fimmu.2022.844866. PubMed DOI PMC

She X, Shen S, Chen G, Gao Y, Ma J, Gao Y, Liu Y, Gao G, Zhao Y, Wang C, et al. Immune surveillance of brain metastatic cancer cells is mediated by IFITM1. EMBO J. 2023;42:e111112. doi: 10.15252/embj.2022111112. PubMed DOI PMC

Saveanu L, van Endert P. The role of insulin-regulated aminopeptidase in MHC class I antigen presentation. Front Immunol. 2012;3:57. doi: 10.3389/fimmu.2012.00057. PubMed DOI PMC

Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–172. doi: 10.1111/j.1600-065X.2009.00782.x. PubMed DOI PMC

Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, Janeway CA, Jr, Flavell RA. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 1996;273:1864–1867. doi: 10.1126/science.273.5283.1864. PubMed DOI

Djureinovic D, Wang M, Kluger HM. Agonistic CD40 antibodies in cancer treatment. Cancers (Basel) 2021;13:1302. doi: 10.3390/cancers13061302. PubMed DOI PMC

Yang Y, Sanders AJ, Ruge F, Dong X, Cui Y, Dou QP, Jia S, Hao C, Ji J, Jiang WG. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Am J Cancer Res. 2021;11:5917–5932. PubMed PMC

Jing L, An Y, Cai T, Xiang J, Li B, Guo J, Ma X, Wei L, Tian Y, Cheng X, et al. A subpopulation of CD146+ macrophages enhances antitumor immunity by activating the NLRP3 inflammasome. Cell Mol Immunol. 2023;20:908–923. doi: 10.1038/s41423-023-01047-4. PubMed DOI PMC

Duan H, Jing L, Jiang X, Ma Y, Wang D, Xiang J, Chen X, Wu Z, Yan H, Jia J, et al. CD146 bound to LCK promotes T cell receptor signaling and antitumor immune responses in mice. J Clin Invest. 2021;131:e148568. doi: 10.1172/JCI148568. PubMed DOI PMC

Yánez DC, Ross S, Crompton T. The IFITM protein family in adaptive immunity. Immunology. 2020;159:365–372. doi: 10.1111/imm.13163. PubMed DOI PMC

Cai Y, Ji W, Sun C, Xu R, Chen X, Deng Y, Pan J, Yang J, Zhu H, Mei J. Interferon-induced transmembrane protein 3 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Front Immunol. 2021;12:704965. doi: 10.3389/fimmu.2021.704965. PubMed DOI PMC

Shen C, Li YJ, Yin QQ, Jiao WW, Li QJ, Xiao J, Sun L, Xu F, Li JQ, Qi H, Shen AD. Identification of differentially expressed transcripts targeted by the knockdown of endogenous IFITM3. Mol Med Rep. 2016;14:4367–4373. doi: 10.3892/mmr.2016.5777. PubMed DOI